Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Bristol-Myers Squibb (BMY) and reduced the price target from $58 to $51.
February 06, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Bristol-Myers Squibb but lowered the price target from $58 to $51.
The reduction in price target by a significant financial institution like Wells Fargo, despite maintaining the stock's rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a revised expectation of the stock's future performance, potentially influencing its market price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100